Numerous isoforms of CAPS1 are known to exist, the lower molecular weight bands seen in the immunoblot image are likely to be these isoforms. This CAPS1 antibody is predicted to be specific to CAPS1 and not recognize CAPS2.
Purification
CAPS1 Antibody is affinity chromatography purified via peptide column.
Immunogène
CAPS1 antibody was raised against a 20 amino acid synthetic peptide near the carboxy terminus of the human CAPS1. The immunogen is located within the last 50 amino acids of CAPS1.
CADPS
Reactivité: Humain, Souris, Rat
WB, ELISA, IHC (p), IF
Hôte: Lapin
Polyclonal
unconjugated
Indications d'application
CAPS1 antibody can be used for detection of CAPS1 by Western blot at 0.5 - 1 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 5 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in rat samples, Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
CAPS1 Antibody is supplied in PBS containing 0.02 % sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
-20 °C,4 °C
Stockage commentaire
CAPS1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
CAPS1 Antibody: CAPS1 and its related protein CAPS2 encode novel neural/endocrine-specific cytosolic and peripheral membrane proteins. Both are essential components of the synaptic vesicle priming machinery and are required for the Ca2+-regulated exocytosis of secretory vesicles, CAPS-deficienct neurons contain no or very few fusion competent synaptic vesicles, causing a selective impairment of fast phasic transmitter release. CAPS1 acts at a stage in exocytosis that follows ATP-dependent priming, which involves the essential synthesis of phosphatidylinositol 4, 5-bisphosphate and is thought to be a specific regulator of large dense-core vesicle fusion.